Search results
Showing 2851 to 2900 of 4086 results for patient
This indicator covers the percentage of patients with non-diabetic hyperglycaemia who have had an HbA1c test or FPG test in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM150
This indicator covers the establishing and maintaining of a register of all patients with a diagnosis of non-diabetic hyperglycaemia. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM148
This indicator covers the percentage of patients with diabetes with a record of testing of foot sensation using a 10 g monofilament within the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM131
Listen About this episode When the right technology reaches the right patient, lives change. In this episode of NICE Talks, we hear...
Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer [TSID11769]
Awaiting development Reference number: GID-TA11088 Expected publication date: TBC
Myocardial infarction: measurement of ejection fraction (IND75)
This indicator covers the proportion of patients with acute myocardial infarction with measurement of left ventricular ejection fraction before discharge. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG94
This indicator covers registering patients with a clinical diagnosis of COPD before (start date), and patients with a clinical diagnosis of COPD on or after (start date) whose diagnosis has been confirmed by a quality assured post bronchodilator spirometry FEV1/FVC ratio below 0.7 between 3 months before or 3 months after diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM169
Transvaginal Ultrasound-Guided Radiofrequency Ablation (RFA) for Uterine Fibroids
Awaiting development Reference number: GID-HTG10171 Expected publication date: TBC
Awaiting development Reference number: GID-TA11040 Expected publication date: TBC
Consultation on changes to technology appraisals and highly specialised technologies
arrangements for funding others more clear. The proposed changes will benefit patients by providing access to the most effective and...
Bipolar, schizophrenia and other psychoses: cervical screening (50 to 64 years) (IND214)
This indicator covers the percentage of women aged 50 or over and who have not attained the age of 65 with schizophrenia, bipolar affective disorder and other psychoses whose notes record that a cervical screening test has been performed in the preceding 5 years and 6 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM196
Bipolar, schizophrenia and other psychoses: cervical screening (25 to 49 years) (IND213)
This indicator covers the percentage of women aged 25 or over and who have not attained the age of 50 with schizophrenia, bipolar affective disorder and other psychoses whose notes record that a cervical screening test has been performed in the preceding 3 years and 6 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM195
Awaiting development Reference number: GID-TA11705 Expected publication date: TBC
Awaiting development Reference number: GID-TA11691 Expected publication date: TBC
Awaiting development Reference number: GID-TA10833 Expected publication date: TBC
Evidence-based recommendations on removing wisdom teeth in adults.
Lower limb deep vein valve reconstruction for chronic deep venous incompetence (HTG141)
Evidence-based recommendations on lower limb deep vein valve reconstruction for chronic deep venous incompetence. This involves restructuring valves in the deep veins of the legs by various surgical techniques, such as using stitches to repair the valve.
View recommendations for HTG141Show all sections
Sections for HTG141
Radiofrequency tissue reduction for turbinate hypertrophy (HTG343)
Evidence-based recommendations on radiofrequency tissue reduction for turbinate hypertrophy. This involves using radiofrequency energy to close blood vessels that can cause swelling and destroy excess tissue.
View recommendations for HTG343Show all sections
Awaiting development Reference number: GID-TA11756 Expected publication date: TBC
Awaiting development Reference number: GID-TA11668 Expected publication date: TBC
Awaiting development Reference number: GID-TA11841 Expected publication date: TBC
Camlipixant for treating refractory or unexplained chronic cough [ID6722]
Awaiting development Reference number: GID-TA11707 Expected publication date: TBC
Awaiting development Reference number: GID-TA11843 Expected publication date: TBC
Awaiting development Reference number: GID-TA11849 Expected publication date: TBC
Tiratricol for treating Allan–Herndon–Dudley syndrome [ID6217]
Awaiting development Reference number: GID-TA11192 Expected publication date: TBC
Eneboparatide for treating chronic hypoparathyroidism [TSID12145]
Awaiting development Reference number: GID-TA11713 Expected publication date: TBC
Edaravone for treating amyotrophic lateral sclerosis [TSID11869]
Awaiting development Reference number: GID-TA11362 Expected publication date: TBC
Awaiting development Reference number: GID-TA11059 Expected publication date: TBC
WP1048 for treating grass pollen allergy in people aged 18 to 60 [TSID10467]
Awaiting development Reference number: GID-TA11305 Expected publication date: TBC
Awaiting development Reference number: GID-TA11271 Expected publication date: TBC
Awaiting development Reference number: GID-TA11826 Expected publication date: TBC
Awaiting development Reference number: GID-TA11830 Expected publication date: TBC
Awaiting development Reference number: GID-TA11623 Expected publication date: TBC
Secukinumab for treating relapsed polymyalgia rheumatica [ID6599]
Awaiting development Reference number: GID-TA11806 Expected publication date: TBC
Awaiting development Reference number: GID-TA11332 Expected publication date: TBC
Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over [TSID11777]
Awaiting development Reference number: GID-TA11292 Expected publication date: TBC
Awaiting development Reference number: GID-TA11150 Expected publication date: TBC
Gantenerumab for treating early Alzheimer's disease [TSID10668]
Awaiting development Reference number: GID-TA11072 Expected publication date: TBC
Awaiting development Reference number: GID-TA11226 Expected publication date: TBC
Awaiting development Reference number: GID-TA11227 Expected publication date: TBC
Awaiting development Reference number: GID-TA11527 Expected publication date: TBC
Awaiting development Reference number: GID-TA11069 Expected publication date: TBC
Awaiting development Reference number: GID-TA11050 Expected publication date: TBC
Awaiting development Reference number: GID-TA11815 Expected publication date: TBC
Treprostinil diethanolamine for treating pulmonary arterial hypertension [ID6366]
Awaiting development Reference number: GID-TA11123 Expected publication date: TBC
Awaiting development Reference number: GID-TA11532 Expected publication date: TBC
Awaiting development Reference number: GID-TA11837 Expected publication date: TBC
Awaiting development Reference number: GID-TA11846 Expected publication date: TBC
Awaiting development Reference number: GID-TA11752 Expected publication date: TBC
Awaiting development Reference number: GID-TA11425 Expected publication date: TBC